TY - JOUR
T1 - Melatonin for prevention of metabolic side-effects of olanzapine in patients with first-episode schizophrenia
T2 - Randomized double-blind placebo-controlled study
AU - Modabbernia, Amirhossein
AU - Heidari, Parvaneh
AU - Soleimani, Robabeh
AU - Sobhani, Abdolrasoul
AU - Roshan, Zahra Atrkar
AU - Taslimi, Shervin
AU - Ashrafi, Mandana
AU - Modabbernia, Mohammad Jafar
N1 - Funding Information:
This study was supported by a grant from Guilan University of Medical Sciences to Prof. Mohammad Jafar Modabbernia (grant number: 9277 ).
PY - 2014
Y1 - 2014
N2 - We aimed to determine the efficacy of melatonin 3mg/day in prevention of olanzapine-induced metabolic side-effects. In a randomized double-blind placebo-controlled study, 48 patients with first-episode schizophrenia who were eligible for olanzapine treatment, were randomly assigned to olanzapine plus either melatonin 3mg/day or matched placebo for eight weeks. Anthropometric and metabolic parameters as well as psychiatric symptoms using The Positive and Negative Syndrome Scale (PANSS) were assessed at baseline, week 4, and 8. Primary outcome measure was the change from baseline in weight at week 8. Data were analyzed using t-test, Mann-Whitney U test, and mixed-effects model. Thirty-six patients had at least one post-baseline measurement. At week eight, melatonin was associated with significantly less weight gain [mean difference (MD)=3.2kg, P=0.023], increase in waist circumference [MD=2.83cm, P=0.041] and triglyceride concentration [MD=62mg/dl, P=0.090 (nearly significant)] than the placebo. Changes in cholesterol, insulin, and blood sugar concentrations did not differ significantly between the two groups. Patients in the melatonin group experienced significantly more reduction in their PANSS scores [MD=12.9 points, P=0.014] than the placebo group. No serious adverse events were reported. To summarize, in patients treated with olanzapine, short-term melatonin treatment attenuates weight gain, abdominal obesity, and hypertriglyceridemia. It might also provide additional benefit for treatment of psychosis.
AB - We aimed to determine the efficacy of melatonin 3mg/day in prevention of olanzapine-induced metabolic side-effects. In a randomized double-blind placebo-controlled study, 48 patients with first-episode schizophrenia who were eligible for olanzapine treatment, were randomly assigned to olanzapine plus either melatonin 3mg/day or matched placebo for eight weeks. Anthropometric and metabolic parameters as well as psychiatric symptoms using The Positive and Negative Syndrome Scale (PANSS) were assessed at baseline, week 4, and 8. Primary outcome measure was the change from baseline in weight at week 8. Data were analyzed using t-test, Mann-Whitney U test, and mixed-effects model. Thirty-six patients had at least one post-baseline measurement. At week eight, melatonin was associated with significantly less weight gain [mean difference (MD)=3.2kg, P=0.023], increase in waist circumference [MD=2.83cm, P=0.041] and triglyceride concentration [MD=62mg/dl, P=0.090 (nearly significant)] than the placebo. Changes in cholesterol, insulin, and blood sugar concentrations did not differ significantly between the two groups. Patients in the melatonin group experienced significantly more reduction in their PANSS scores [MD=12.9 points, P=0.014] than the placebo group. No serious adverse events were reported. To summarize, in patients treated with olanzapine, short-term melatonin treatment attenuates weight gain, abdominal obesity, and hypertriglyceridemia. It might also provide additional benefit for treatment of psychosis.
KW - Glucose
KW - Lipid
KW - Melatonin
KW - Olanzapine
KW - Schizophrenia
KW - Weight gain
UR - http://www.scopus.com/inward/record.url?scp=84897388149&partnerID=8YFLogxK
U2 - 10.1016/j.jpsychires.2014.02.013
DO - 10.1016/j.jpsychires.2014.02.013
M3 - Article
C2 - 24607293
AN - SCOPUS:84897388149
SN - 0022-3956
VL - 53
SP - 133
EP - 140
JO - Journal of Psychiatric Research
JF - Journal of Psychiatric Research
IS - 1
ER -